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Abstract
Background: In familial hypertrophic cardiomyopathy (FHC), asymmetric left ventricular (LV)
hypertrophy has been considered to be the predominant phenotypic expression, whereas right
ventricular (RV) involvement is still ambiguous. In most cases, the right ventricle remains
unaffected until secondary pulmonary hypertension develops. Several FHC-causing mutations
of genes encoding sarcomere-related proteins have been identified which are transmitted in an
autosomal-dominant manner.
Methods: We report the case of  a 61 year old member of a Catalan family with a Arg723Gly
missense mutation of the b-myosin heavy chain (b-MHC), that is associated with a malignant
phenotype characterized by sudden cardiac death and heart failure. Because of progressive
systolic LV dysfunction, the patient received a heart transplant in 2003.
Results: Molecular analysis of the myocardial tissue of the explanted heart, taken from the left
and right ventricle, showed a similar deviation of the ratio of mutant vs wild type mRNA of the
b-MHC of 71.8 ± 5% and 68.5 ± 3%, respectively. This finding was confirmed for LV biopsies of
this patient on protein level, showing a similar proportion of mutated b-myosin. But since the
patient is heterozygous for the b-MHC mutation and the mutation is located in a coding region,
the relative increase of the expression of the mutant allele is unexpected. It has been demonstrated
before by our group for several b-MHC mutations that the relative abundance of mutated mRNA/
/protein correlates with the clinical severity of the disease. But since the right ventricle shows no
(or only minor) manifestation in terms of hypertrophy or dysfunction, the level of mRNA and
protein expression is not the only factor responsible for the development of the phenotype of FHC.
Conclusions: Several mechanisms through which cardiac stresses may incite maladaptive
cardiac remodeling primarily of the left ventricle that result in myocardial hypertrophy and
heart failure are proposed. One of those triggers could be the enhanced work load of the left
ventricle, especially if a LV outflow tract gradient is present, in contrast to the lesser demands
to the right ventricle which is adapted to the low pressure system of the pulmonary circulation.
Further studies are needed to confirm the results of this case, as well as functional studies
involving both ventricles. (Cardiol J 2010; 17, 5: 518–522)
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Introduction
Familial hypertrophic cardiomyopathy (FHC)
is the commonest inherited cardiac disease that is
characterized by left ventricular (LV) hypertrophy,
predominantly of the interventricular septum. The
clinical spectrum of the disease varies greatly, rang-
ing from asymptomatic mutation carriers to a small
subset of patients who develop progressive systol-
ic heart failure and LV dilatation, with a reported
prevalence of 2.4% to 15% in different series [1].
In about one third of genetically characterized FHC
families, point mutations of the b-MHC gene were
shown to cause the disease [2]. In 2000, Enjuto et
al. [3] reported on a new Arg723Gly missense mu-
tation in the converter region of the b-MHC in three
Catalan families. This mutation was associated with
sudden death and end-stage heart failure. In one of
these families, nine gene mutation carriers were
found, all showing distinct morphologic manifestations
of the disease in the left ventricle on echocardiography
(ECHO). To address the interesting phenomenon
that the phenotype of FHC is predominantly found
in the left ventricle, we analysed the ratio of mutant
versus wild type b-MHC mRNA in myocardial tissue
of the left and right ventricles of a member of one of
the Catalan families. This patient had initially devel-
oped the classical clinical phenotype of FHC with
asymmetrical septal hypertrophy and diastolic dys-
function, which then further progressed into LV
dilatation and systolic heart failure. Consequently,
the patient received a heart transplant aged 55.
Methods
The patient, who is now aged 61, of the geno-
typed Catalan family 26 (patient II-5, Enjuto et al.),
a heterozygous carrier of a point mutation
(Arg723Gly) of the b-MHC, was diagnosed with
FHC at the age of 31. He developed the classical
spectrum of symptoms of FHC over subsequent
years, such as atypical chest pain, dyspnea (NYHA
II) and palpitations. Pharmacological treatment was
started with a moderate dosage of the calcium chan-
nel blocker verapamil (120 mg to 240 mg per day).
In 1997, he suffered a syncopal episode with
runs of sustained ventricular tachycardia, based on
which he received an automatic implantable defibril-
lator. During that time, a comprehensive cardiologic
study was performed showing on ECHO an asym-
metric LV hypertrophy with a maximum thickness
of the septum of 16 mm and of 13 mm of the poste-
rior wall in the parasternal long axis (Fig. 1A). The
ejection fraction (EF) was moderately decreased to
40% and the LV end-diastolic diameter was slight-
ly increased to 57 mm. The mitral deceleration time
of 265 ms was indicative of diastolic dysfunction that
was confirmed angiographically with an end-dias-
tolic pressure in the left ventricle of 20 mm Hg. The
coronary arteries were normal. The right ventricle
A B
Figure 1. A. Six years prior to heart transplantation (1997), in the parasternal long axis view, assymmetric septal
hypertrophy (septum diameter 16 mm, see double arrow, posterior wall 13 mm), and a moderately increased left
ventricular cavity size (end-diastolic diameter 57 mm) was recorded. The function and size of the right ventricle was
normal; B. In the four chamber view, the interpretation of the recording concerning the right ventricle is limited, but
it was documented as non-dilated; Ao — aortic root, LA — left atrium; LV — left ventricular cavity; RV — right
ventricular chamber.
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showed no obvious manifestation of the disease on
ECHO at that time (Fig. 1A, B).
From that point on, a slow but progressive de-
terioration of the functional status of the patient
developed, which became severe (NYHA III–IV)
after the commencement of repeated episodes of
atrial fibrillation in 2001. On at least two occasions,
he suffered acute LV failure with pulmonary oede-
ma, and he persisted in severe functional limitation
despite good heart rate control. During that time,
he was treated with furosemide (40–80 mg per day),
amiodarone, digoxine, low dosages of enalapril, and
oral anticoagulation following a TIA (transient ce-
rebral ischemic attack) in January 2002. He did not
tolerate beta-blocker therapy because of severe low
output. Echocardiographic data from May 2002
showed an ejection fraction that had declined to
30%, an LV end-diastolic diameter of 65 mm with
less prominent septal hypertrophy with 13 mm, and
a mitral diastolic flow showing a restrictive filling
pattern of the left ventricle. The invasive hemody-
namic data displayed the clinical picture of progres-
sive low output syndrome and LV backward failure
with a mean pulmonary artery pressure of 64/24
(40) mm Hg. He was promptly scheduled for heart
transplantation and successfully operated upon in
September 2003. He has done well since then, de-
spite some extracardial problems like advanced
reflux esophagitis, and prostate cancer that is cur-
rently in full remission after radiotherapy.
The study was approved by the local bioethical
committe and all patients gave their informed consent.
Total RNA of each of the nine tissue samples
frozen in liquid nitrogen were isolated by using the
cells to cDNA kit II (Applied Biosystems, USA).
Isolated RNA was reverse transcribed with a com-
mon gene specific primer (5’ TGC CAG GTT GTC
TTG TTC CG 3’). For cDNA amplification two gene
specific primers ([forward primer 5’ CCA ACC GCA
TCC TCT ACG GGG ACT TCC GGC AGA GGG
AT 3’] and [reverse primer 5’ CTT TTT GTA CTC
CAT TCT GGC GAG CAC A 3’]) were used. The
PCR products were digested with NdeII restriction
enzyme for discriminating between the wild type
and the mutated cDNA, which was possible because
the forward primer created an additional restriction
site only in the wild type PCR product. The frag-
ments were separated on a 3.5% agarose gel after
ethidium bromide staining. For relative quantifica-
tion, the intensity profiles of the individual bands
and of an equimolar DNA-standard were obtained
densitometrically. The fraction of mutated mRNA
in each restriction digest was calculated from the
IOD/bp ratio of a fragment exclusively from the
mutant versus the IOD/bp ratio of a fragment ex-
clusively from the wild type or versus the average
of the IOD/bp values of two wild type fragments
(Fig. 2). For each biopsy, 6 ± 2 (mean ± SD) lanes
were analyzed.
Results
Myocardial tissue from a 61 year-old patient
(II-5, Enjuto et al.) of a genotyped Catalan family
was analyzed. The clinical disease spectrum of the
nine mutation carriers of this family ranged from
classical asymmetric LV hypertrophy with or with-
out clinical symptoms to three cases of progressive
Figure 2. On the gel electrophoresis of the digested PCR products (3.5% ethidium bromide agarose gel), the
uppermost 156 base pair (bp) band is derived from the mutant and wild type, the 125 bp exclusively from the mutant
and the 90 bp exclusively from the wild type. The 35 bp fragment, also produced by the digestion of the wild type
PCR product, is not visible owing to its small size (see cartoon below). The cycle numbers (C) are given on top of
each lane (two times 3C and 4C).
DNA Ladder Blank 3C 3C 4C 4CSize
(bp)
400
200
100
35 bp 90 bp
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156 bp
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Mutant
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LV dilation and end-stage systolic heart failure,
which was in some cases age-dependent.
For molecular analysis, four tissue samples were
taken from the right ventricle, and five biopsies from
the anterior, lateral, and inferior wall and the septum
of the left ventricle. We found a significant deviation
from the expected 1:1 ratio between mutant and wild
type myosin. This was similar for LV and right ven-
tricular tissue (RV), with 71.8 ± 5% and 68.5 ± 3%
respectively. The clinical phenotype on ECHO one
year prior to transplantation, though, showed an asym-
metric septal hypertrophy of the left ventricle and
a systolic anterior movement of the anterior mitral
valve (SAM). In addition, a pressure gradient of the
LV outflow tract was present on provocation of 40 mm
Hg. The dimensions and function of the right ventri-
cle were described as normal. During follow up, in con-
formity to the progressive decline in the physical well-
being of the patient, severe LV dilatation and systolic
dysfunction was obvious on ECHO. But even at end
stage LV failure, the right ventricle was not dilated
and showed a normal function (Fig. 3).
Discussion
For several mutations of the b-MHC, current
evidence indicates that there is an association be-
tween disease severity and the fraction of mutated
b-myosin incorporated into the sarcomere [4]. We
have previously shown that this fraction is specific for
a given mutation on the mRNA and protein level [5, 6].
From this Catalan family (including patient II-5),
Tripathi has analyzed the proportion of mutated
b-MHC mRNA in LV tissue and soleus biopsies of
three patients (two brothers and a nephew) and
found a similar ratio of mutated versus wild type
mRNA of 66% on average [4]. All three patients ex-
hibited the phenotype characteristic of hypertrophic
cardiomyopathy, but no overt RV disease. Thus,
the relative amount of mutated b-MHC does not
explain the discrepancy between the disease mani-
festation between the left and right ventricle.
The functional consequence of the Arg723Gly
mutation on a cellular level was recently analyzed
by force measurements on skinned soleus muscle
fibers [7, 8]. The mutation results in reduced com-
pliance and enhanced cross-bridge stiffness of the
muscle fiber that is related to alterations in the most
compliant region of the myosin head, the convert-
er domain of the b-MHC. Several studies have con-
firmed that mutations in the b-MHC gene impair
contractility and induce the release of growth fac-
tors that result in compensatory hypertrophy and
fibroblast proliferation, the histologic hallmark of
FHC [9]. Our findings show a similar expression of
the mutant and wild type allele of the b-MHC in the
left and right ventricle, but hypertrophy only of the
left ventricle indicates that additional triggers are
required for the initiation of the maladaptive com-
pensatory response to the myocyte dysfunction.
Such triggers could be environmental factors such
as increased myocardial wall stress, which may
explain why pathologic cardiac remodelling is pre-
dominantly restricted to the left ventricle as the
chamber of maximal force generation and energy
consumption [10]. Recently, research on the still
unknown unifying mechanism for the development
of cardiac hypertrophy in FHC has focused on the
hypothesis that an imbalance of energy cost and
supply resulting in a chronic ‘energy compromise’
state acts as a potent stimulus for hypertrophy [11].
The clinical observation that excess intraventricu-
lar pressure and thus enhanced energy demand of
the ventricle is triggering myocardial hypertrophy
was supported by the results of the two-year fol-
low-up of FHC patients after elimination of their
outflow tract gradient by septal myectomy, which
induced a significant reduction in wall thickness,
cardiac mass and myocardial collagen [12].
However, one plausible explanation for the dif-
ference in the abundance of myocardial hypertro-
Figure 3. In 2002, one year prior to heart transplantation,
severe dilatation with a left ventricular end-diastolic dia-
meter of 65 mm, a further decrease of the ejection frac-
tion to 30%, and a diminished width of the septum of
12 mm was described. The right ventricle seems to be
smaller in size with slightly increased wall diameter com-
pared to 1997, but this can be partially attributed to the
cardiac cycle the frame was recorded in (mid-diastole).
At that time, the pressure in the pulmonary circulation
was moderately elevated; for abbreviations, see Figure 1.
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phy in FHC between the left and right ventricles
could also be the lack of adequate imaging tools,
since the spatial resolution of two-dimensional
echocardiography is limited and related to that, no
definite standardized values for analysing RV di-
mensions and function have been published [13]. It
was recently demonstrated in an imaging study
using magnetic resonance imaging that morphologic
abnormalities were present in 19 of 46 (41%) pa-
tients with FHC by showing diffuse RV wall thick-
ening but no contractile dysfunction. And in only
one of the 46 FHC patients included in the study,
myocardial fibrosis as the typical hallmark of hyper-
trophic cardiomyopathy was detected by contrast
magnetic resonance imaging as late enhancement
areas in the right ventricle, whereas 26 of 46 pa-
tients (57%) had late enchancement areas within
the LV myocardium.
The cardiomyopathy that predominantly in-
volves the right ventricle is arrhythmogenic right
ventricular cardiomyopathy (ARVCM), characte-
rized by fibroadipocytic replacement of RV cardiac
myocytes. Lombardi et al. [14] showed in a mouse
model that second heart field progenitor cells act
as the cell source of adipocytes in ARVCM. The right
ventricle primarily originates from the second (an-
terior) heart field, as opposed to the left ventricle,
which originates from the primary heart field. The
two heart fields express distinct sets of transcription-
al factors and signalling molecules [15]. It can be
therefore speculated that the different developmen-
tal origins of the left and right ventricle play a role in
the contrast disease manifestations between the two
chambers. However, our data shows that the rela-
tive level of mutated b-MHC mRNA is not affected
by the origin of the ventricles.
Future studies that integrate molecular, biolo-
gical, functional and biochemical data from both the
left and right ventricle should further elucidate the
pathways by which the altered b-MHC results in
pathologic cardiac remodelling. The mechanisms for
the difference in disease manifestation, despite sim-
ilar expression of the b-MHC mutation, should ul-
timately be translated into early therapeutic inter-
ventions to prevent the development of cardiac
hypertrophy in mutation carriers.
Conclusions
Despite heterozygocity of the missense muta-
tion Arg723Gly of the b-MHC, which causes severe
hypertrophic cardiomyopathy, the ratio of mutant
versus wild type myosin mRNA deviates from 1:1.
This deviation is similar in both ventricles. Because
of the evidence of a correlation between the ma-
lignancy of FHC and the fraction of mutant myosin
expressed in the contractile apparatus, the reason
for the development of myocyte hypertrophy prima-
rily in the left ventricle in contrast to the right ven-
tricle is unclear. Our data indicates that the induction
of the process of pathologic cardiac remodeling and
heart failure in FHC depends on additional influenc-
es, like environmental, humoral or genetic factors.
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